0001213900-24-033564.txt : 20240416
0001213900-24-033564.hdr.sgml : 20240416
20240416210920
ACCESSION NUMBER: 0001213900-24-033564
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240412
FILED AS OF DATE: 20240416
DATE AS OF CHANGE: 20240416
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Daewoong Co., Ltd
CENTRAL INDEX KEY: 0001985493
ORGANIZATION NAME:
STATE OF INCORPORATION: M5
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40021
FILM NUMBER: 24849141
BUSINESS ADDRESS:
STREET 1: 244, GALMACHI-RO, JUNGWON-GU
CITY: SEONGNAM-SI, GYEONGGI-DO
STATE: M5
ZIP: 13211
BUSINESS PHONE: 82-2-550-8800
MAIL ADDRESS:
STREET 1: 244, GALMACHI-RO, JUNGWON-GU
CITY: SEONGNAM-SI, GYEONGGI-DO
STATE: M5
ZIP: 13211
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AEON Biopharma, Inc.
CENTRAL INDEX KEY: 0001837607
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 853940478
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 PARK PLAZA
STREET 2: SUITE 1750
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: (949) 354-6499
MAIL ADDRESS:
STREET 1: 5 PARK PLAZA
STREET 2: SUITE 1750
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: Priveterra Acquisition Corp.
DATE OF NAME CHANGE: 20201222
4/A
1
ownership.xml
X0508
4/A
2024-04-12
2024-04-12
0
0001837607
AEON Biopharma, Inc.
AEON
0001985493
Daewoong Co., Ltd
44, GALMACHI-RO, JUNGWON-GU
SEONGNAM-SI, GYEONGGI-DO
M5
13211
KOREA, REPUBLIC OF
0
0
1
0
0
Senior Secured Convertible Note
2024-04-12
4
J
0
10000000
A
2027-04-12
Common Stock
10000000
10000000
I
See footnote
Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. ("DWP"), AEON Biopharma, Inc. ("AEON" or the "Company") and AEON Biopharma Sub, Inc., a subsidiary of the Company ("AEON Sub"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the "Subsequent Convertible Note" or "$10.0 million Note") in the principal amount of $10.0 million on April 12, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 ("Common Stock"), subject to certain conditions and limitations set forth in the $10.0 million Note.
(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the "Maturity Date"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a "Qualified Financing"),
(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the "Automatic Conversion") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate.
Daewoong Co., Ltd., a company organized under the laws of the Republic of Korea, owns 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd., a company organized under the laws of the Republic of Korea; Daewoong Co., Ltd. has voting power and dispositive power over Daewoong Pharmaceutical Co., Ltd. and therefore may be deemed to indirectly own such shares.
Daewoong Co., Ltd., By: /s/ Kyu Sung Lim, Authorized Signatory
2024-04-16